PDF下载 ( 1617 KB)
Clinical study of lamivudine antiviral therapy for chronic hepatitis B
-
-
[1]Lok ASF.Natural history and control of perinatally acquired hepatitis B virus infection[J].Dig Dis, 1992, 10 (1) ∶46. [2]赵英杰, 范希成.慢性乙型肝炎抗病毒治疗的进展[J].寄生虫与感染性疾病, 2004, 2 (1) ∶34 [3]吴志明.人乙型肝炎病毒感染的治疗现状及展望[J].广州医药, 2000, 34 (4) ∶57. [4]Ben-Ari Z, Shmueli D, Mor E, et al.Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation[J].Transplanta-tion, 1997, 63 (3) ∶393-396. [5]Johnson MA, Moore KH, Yuen GJ, et al.Clinica pharmacokinetics of lamivudine[J].Pharmacokinet, 1999, 36 (1) ∶41-66. [6]Lai CL, Chang TT.Extended lamivudine trestment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates:results after3years of therapy[J].Hepatology, 2001, 33 (6) ∶1527-1532. [7]Chang T, Lai C, Liaw Y.Enhanced HbeAg seroconversion rates in Chinese patients on lamivudine[J].Hepatology, 1999, 28∶420A. [8]Yeh CT, Chien RN, Chu CM, et al.Clearance of the origina hepatitis B virus YMDD-motif mutants with emergence of distinc lamivudine-resistant mutants during prolonged lamivudine therapy[J].Hepa-tology, 2000, 31 (6) ∶1318-1326. [9]Mason WS, Cullen J, Saputelli J, et al.Characterization of the antiviral effects of2’-carbodeoxy-guanosine in ducks chronically infected with duck hepatitis B virus[J].Hepatology, 1994, 19 (2) ∶398-411. -
本文二维码
计量
- 文章访问数: 2901
- HTML全文浏览量: 11
- PDF下载量: 789
- 被引次数: 0
下载:
